GOHIBIC Trademark

Trademark Overview

On Monday, August 1, 2022, a trademark application was filed for GOHIBIC with the United States Patent and Trademark Office. The USPTO has given the GOHIBIC trademark a serial number of 76720933. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Monday, June 9, 2025. This trademark is owned by InflaRx GmbH. The GOHIBIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and medical preparations targeting acute and chronic inflammation
gohibic

General Information

Serial Number76720933
Word MarkGOHIBIC
Filing DateMonday, August 1, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateMonday, June 9, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2024

Trademark Statements

Goods and ServicesPharmaceuticals and medical preparations targeting acute and chronic inflammation

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 1, 2024
Primary Code005
First Use Anywhere DateThursday, July 27, 2023
First Use In Commerce DateThursday, July 27, 2023

Trademark Owner History

Party NameInflaRx GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressJena 07745
DE
Party NameInflaRx GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
Address07745 Jena
DE

Trademark Events

Event DateEvent Description
Thursday, May 2, 2024REQUEST FOR TRANSFORMATION PROCESSED - PARTIAL
Thursday, May 2, 2024ASSIGNED TO EXAMINER
Tuesday, May 7, 2024APPLICATION FILING RECEIPT MAILED
Wednesday, May 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 10, 2024SUSPENSION LETTER WRITTEN
Wednesday, May 29, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, May 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 29, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 29, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 10, 2024LETTER OF SUSPENSION E-MAILED
Friday, May 10, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, May 29, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, May 30, 2024ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, June 19, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 5, 2025USE AMENDMENT FILED
Wednesday, February 5, 2025TEAS STATEMENT OF USE RECEIVED
Tuesday, September 3, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 16, 2025STATEMENT OF USE PROCESSING COMPLETE
Monday, June 9, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, June 9, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, April 16, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL

Related Keywords

gohibic chronic inflammation acute targeting medical preparations pharmaceuticals